Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > COLUMN
COLUMN
- Digital and Cultural Transformation in Japanese Pharmaceuticals
August 13, 2021
- How Manufacturers Can Optimize Wholesaler Relationships and Leverage Wholesalers to Support Business Strategy
July 13, 2021
- Does Your Company Want to Increase Its Diversity?
July 5, 2021
- 5 Lessons in 5 Years from Rocking the Bag
June 17, 2021
- Pricing Reform in Japan - How Manufacturers Can Ensure Fair Compensation for Value and Innovation
May 28, 2021
- Set the Stage for an Exceptional Customer Experience
May 21, 2021
- Pricing Reform in Japan: How Must Life Science Companies Evolve?
April 23, 2021
- Do You Attract or Repel Winning Candidates?
April 16, 2021
- The Future of Customer Engagement in Japan’s Life Science Industry: One Year Post-COVID
March 19, 2021
- Bring Your A-Game to Your Next Video Call
March 11, 2021
- What Personal Biases Influence Your Hires?
February 19, 2021
- Is Your Company Culture Being a Victim of COVID-19?
January 8, 2021
- It’s the Everyday Leaders Your Organization Needs
December 11, 2020
- Let’s Be Grateful for the Chaos of the Year That Was
November 18, 2020
- Empower Smarter Decision Making with Big Data
October 23, 2020
- 5 Improvements when Recruiting Female Employees
September 25, 2020
- Think Differently for Post-Pandemic Success
August 14, 2020
- The Crisis That Ignited a Workplace Revolution
July 6, 2020
- Smart Strategies for Building Your Dream Team
March 17, 2020
- A Peek into the Digital Pharmaceutical Industry
November 21, 2019
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…